GICS Sector : Healthcare
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
Aug -01
IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders
Jul -01
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
Jul -01
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
May -13
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
Feb -05
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Feb -01
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Jan -28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Jan -26
IGM Biosciences' Engineered Immunoglobulin M Antibodies' 11.3% growth is driven by increasing adoption in cancer treatment, rising demand for targeted therapies, and advancements in antibody engineering. Additionally, growing investments in R&D, strategic partnerships, and expanding applications in autoimmune diseases contribute to the segment's rapid growth.
IGM-2323 is a Bispecific Antibody targeting CD20 and CD3 for the treatment of B-cell Non-Hodgkin Lymphoma
IGM-2543 is a Bispecific Antibody targeting CD38 and CD3 for the treatment of Multiple Myeloma
IGM-8444 is a Bispecific Antibody targeting PD-1 and CD28 for the treatment of Solid Tumors
The threat of substitutes for IGM Biosciences, Inc. is moderate due to the presence of alternative treatments and therapies for cancer and other diseases.
The bargaining power of customers for IGM Biosciences, Inc. is low due to the company's specialized products and limited competition in the biotech industry.
The bargaining power of suppliers for IGM Biosciences, Inc. is moderate due to the company's reliance on a few key suppliers for raw materials and equipment.
The threat of new entrants for IGM Biosciences, Inc. is high due to the growing demand for biotech products and the increasing number of startups and established companies entering the market.
The intensity of rivalry for IGM Biosciences, Inc. is high due to the competitive nature of the biotech industry and the presence of established companies and new entrants vying for market share.
| Value | |
|---|---|
| Debt Weight | 16.62% |
| Debt Cost | 3.95% |
| Equity Weight | 83.38% |
| Equity Cost | 5.23% |
| WACC | 5.02% |
| Leverage | 19.93% |
Value: 1.3
Growth: 5.2
Quality: 8.9
Yield: 0.0
Momentum: 9.5
Volatility: 1.7
1-Year Total Return ->
Value: 9.4
Growth: 7.1
Quality: 4.3
Yield: 0.0
Momentum: 0.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.2
Growth: 3.9
Quality: 3.6
Yield: 0.0
Momentum: 6.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.6
Growth: 3.2
Quality: 3.7
Yield: 0.0
Momentum: 4.0
Volatility: 1.7
1-Year Total Return ->
Value: 8.0
Growth: 4.3
Quality: 6.1
Yield: 0.0
Momentum: 0.0
Volatility: 0.3
1-Year Total Return ->
Value: 6.6
Growth: 5.0
Quality: 3.5
Yield: 0.0
Momentum: 1.5
Volatility: 1.7
1-Year Total Return ->